Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus high-dose furazolidone for Helicobacter pylori eradication
IRCT20160118026097N6Phase 3Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of furazolidone in Helicobacter pylori infection (2 arms), sponsored by Golestan University of Medical Sciences. Primary endpoints: Reduce side effects and Discontinue treatment. Started Jul 2016; status: completed.
02
Drugs
furazolidone
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20160118026097N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160118026097N6.